Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 33 Records) |
| Query Trace: Neoplasms and AKR1C3[original query] |
|---|
| Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Human genetics 2007 Apr 121 (2): 161-8. Lan Qing, Zheng Tongzhang, Shen Min, Zhang Yawei, Wang Sophia S, Zahm Shelia H, Holford Theodore R, Leaderer Brian, Boyle Peter, Chanock Steph |
| Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007 May 16 (5): 969-78. Cunningham Julie M, Hebbring Scott J, McDonnell Shannon K, Cicek Mine S, Christensen G Bryce, Wang Liang, Jacobsen Steven J, Cerhan James R, Blute Michael L, Schaid Daniel J, Thibodeau Stephen |
| Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007 Jan 16 (1): 165-8. Berndt Sonja I, Chatterjee Nilanjan, Huang Wen-Yi, Chanock Stephen J, Welch Robert, Crawford E David, Hayes Richard |
| Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008 Oct 29 (10): 1955-62. Figueroa Jonine D, Malats Núria, García-Closas Montserrat, Real Francisco X, Silverman Debra, Kogevinas Manolis, Chanock Stephen, Welch Robert, Dosemeci Mustafa, Lan Qing, Tardón Adonina, Serra Consol, Carrato Alfredo, García-Closas Reina, Castaño-Vinyals Gemma, Rothman Nathani |
| The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. International journal of cancer. Journal international du cancer 2008 Jun 122 (11): 2511-6. Vaarala Markku H, Mattila Henna, Ohtonen Pasi, Tammela Teuvo L J, Paavonen Timo K, Schleutker Johan |
| Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. The Journal of steroid biochemistry and molecular biology 2009 Sep 116 (3-5): 134-53. Plourde Marie, Ferland Alexandra, Soucy Penny, Hamdi Yosr, Tranchant Martine, Durocher Francine, Sinilnikova Olga, Luu The Van, , Simard Jacqu |
| Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk. American journal of epidemiology 2009 Nov 170 (10): 1241-9. Reding Kerryn W, Li Christopher I, Weiss Noel S, Chen Chu, Carlson Christopher S, Duggan David, Thummel Kenneth E, Daling Janet R, Malone Kathleen |
| Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy. Breast cancer research and treatment 2012 Jan 131 (2): 653-61. Hein R, Abbas S, Seibold P, Salazar R, Flesch-Janys D, Chang-Claude |
| Variation in genes encoding the neuroactive steroid synthetic enzymes 5a-reductase type 1 and 3a-reductase type 2 is associated with alcohol dependence. Alcoholism, clinical and experimental research 2011 May 35 (5): 946-52. Milivojevic Verica, Kranzler Henry R, Gelernter Joel, Burian Linda, Covault Jonath |
| Basal and Regulatory Promoter Studies of the AKR1C3 Gene in Relation to Prostate Cancer. Frontiers in pharmacology 2012 3 151. Schulze Jenny J, Karypidis Helena, Ekström Le |
| Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer epidemiology 2012 Aug 36 (4): 347-53. Kwon Erika M, Holt Sarah K, Fu Rong, Kolb Suzanne, Williams Gabrielle, Stanford Janet L, Ostrander Elaine |
| Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients. British journal of clinical pharmacology 2013 Jun 75 (6): 1497-505. Voon Pei Jye, Yap Hui Ling, Ma Cho-Yee-Thu, Lu Fan, Wong Andrea L A, Sapari Nur Sabrina, Soong Richie, Soh Thomas I P, Goh Boon-Cher, Lee How-Sung, Lee Soo-Ch |
| Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PloS one 2013 8 (1): 1. Yu CC, Huang SP, Lee YC, Huang CY, Liu CC, Hour TC, Huang CN, You BJ, Chang TY, Huang CH, Bao BY |
| [Molecular epidemiology study in Xuanwei: the relationship among ?coal type, genotype and lung cancer risk]. Zhongguo fei ai za zhi = Chinese journal of lung cancer 2015 Jan 18 (1): 16-22. Li Jihua, He Jun, Tang Rui, Hu Wei, Lan Qing, He Xingzhou, Li Yun, Zhang Yunshe |
| Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism? BMC urology 2016 16 (1): 48. Karunasinghe Nishi, Zhu Yifei, Han Dug Yeo, Lange Katja, Zhu Shuotun, Wang Alice, Ellett Stephanie, Masters Jonathan, Goudie Megan, Keogh Justin, Benjamin Benji, Holmes Michael, Ferguson Lynnette |
| Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. The pharmacogenomics journal 2016 Aug . Hertz D L, Kidwell K M, Seewald N J, Gersch C L, Desta Z, Flockhart D A, Storniolo A-M, Stearns V, Skaar T C, Hayes D F, Henry N L, Rae J |
| Association of AKR1C3 Polymorphisms with Bladder Cancer. Urology journal 2016 13 (2): 2615-21. Tiryakioglu N Ozan, Tunali Nagehan Ers |
| Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts. PloS one 2018 13 (6): e0199122. Karunasinghe Nishi, Ambs Stefan, Wang Alice, Tang Wei, Zhu Shuotun, Dorsey Tiffany H, Goudie Megan, Masters Jonathan G, Ferguson Lynnette |
Identification of novel epithelial ovarian cancer loci in women of African ancestry.
International journal of cancer 2019 Aug . Manichaikul Ani, Peres Lauren C, Wang Xin-Qun, Barnard Mollie E, Chyn Deanna, Sheng Xin, Du Zhaohui, Tyrer Jonathan, Dennis Joseph, Schwartz Ann G, Cote Michele L, Peters Edward, Moorman Patricia G, Bondy Melissa, Barnholtz-Sloan Jill S, Terry Paul, Alberg Anthony J, Bandera Elisa V, Funkhouser Ellen, Wu Anna H, Pearce Celeste Leigh, Pike Malcom, Setiawan Veronica Wendy, Haiman Christopher A, , , Palmer Julie R, LeMarchand Loic, Wilkens Lynne R, Berchuck Andrew, Doherty Jennifer A, Modugno Francesmary, Ness Roberta, Moysich Kirsten, Karlan Beth Y, Whittemore Alice S, McGuire Valerie, Sieh Weiva, Lawrenson Kate, Gayther Simon, Sellers Thomas A, Pharoah Paul, Schildkraut Joellen M, |
| Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand. PloS one 2019 14 (5): e0217373. Karunasinghe Nishi, Symes Eva, Gamage Amy, Wang Alice, Murray Pam, Zhu Shuotun, Goudie Megan, Masters Jonathan, Ferguson Lynnette |
| Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy. Urologic oncology 2020 7 38 (11): 849.e11-849.e18. Shiota Masaki, Endo Satoshi, Fujimoto Naohiro, Tsukahara Shigehiro, Ushijima Miho, Kashiwagi Eiji, Takeuchi Ario, Inokuchi Junichi, Uchiumi Takeshi, Eto Masatos |
| Genetic 3'UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients. Scientific reports 2020 Mar 10 (1): 5736. Pamu?a-Pi?at Jolanta, T?cza Karolina, Kalinowska-Herok Magdalena, Grzybowska E |
| Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics 2021 9 22 (14): 885-901. Petrykey Kateryna, Rezgui Aziz M, Guern Mathilde Le, Beaulieu Patrick, St-Onge Pascal, Drouin Simon, Bertout Laurence, Wang Fan, Baedke Jessica L, Yasui Yutaka, Hudson Melissa M, Raboisson Marie-Josée, Laverdière Caroline, Sinnett Daniel, Andelfinger Gregor U, Krajinovic Ma |
| Interactions between exposure to polycyclic aromatic hydrocarbons and xenobiotic metabolism genes, and risk of breast cancer. Breast cancer (Tokyo, Japan) 2021 Aug . Lee Derrick G, Schuetz Johanna M, Lai Agnes S, Burstyn Igor, Brooks-Wilson Angela, Aronson Kristan J, Spinelli John |
| The association between missense polymorphisms in SRD5A2 and HSD3B1 and treatment failure with abiraterone for castration-resistant prostate cancer. The pharmacogenomics journal 2021 3 21 (4): 440-445. Shiota Masaki, Akamatsu Shusuke, Narita Shintaro, Sumiyoshi Takayuki, Fujiwara Maki, Uchiumi Takeshi, Ogawa Osamu, Habuchi Tomonori, Eto Masatos |
| Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel. BMC medicine 2022 Jan 20 (1): 48. Gurioli Giorgia, Conteduca Vincenza, Brighi Nicole, Scarpi Emanuela, Basso Umberto, Fornarini Giuseppe, Mosca Alessandra, Nicodemo Maurizio, Banna Giuseppe Luigi, Lolli Cristian, Schepisi Giuseppe, Ravaglia Giorgia, Bondi Isabella, Ulivi Paola, De Giorgi U |
| Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions. Scientific reports 2022 1 12 (1): 55. Karunasinghe Nishi, Minas Tsion Zewdu, Bao Bo-Ying, Lee Arier, Wang Alice, Zhu Shuotun, Masters Jonathan, Goudie Megan, Huang Shu-Pin, Jenkins Frank J, Ferguson Lynnette |
| Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study. JCO precision oncology 2023 3 7 e2200580. Larkin Trisha, Kashif Reema, Elsayed Abdelrahman H, Greer Beate, Mangrola Karna, Raffiee Roya, Nguyen Nam, Shastri Vivek, Horn Biljana, Lamba Jatinder |
| A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 11 169 115890. Stefan A J Buck, Marinda Meertens, Frederiek M F van Ooijen, Esther Oomen-de Hoop, Evert de Jonge, Marieke J H Coenen, Andries M Bergman, Stijn L W Koolen, Ronald de Wit, Alwin D R Huitema, Ron H N van Schaik, Ron H J Mathijss |
| Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate cancer and prostatic diseases 2024 7 . Andrew W Hahn, Rebecca S Tidwell, Patrick G Pilie, Yao Yu, Jingjing Liu, Devaki Shilpa Surasi, Mark Titus, Jianhua Zhang, Neha Venkatesh, Theocharis Panaretakis, Justin R Gregg, Amado J Zurita, Bilal A Siddiqui, Paul G Corn, Sumit K Subudhi, Pavlos Msaouel, Efstratios Koutroumpakis, Chad D Huff, Ana Aparicio, Jennifer L McQuade, Daniel E Frigo, Christopher J Logothet |
- Page last reviewed:Feb 1, 2024
- Content source: